Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Upcoming FDA Events & PDUFA Dates

MarketBeat's Upcoming FDA Events calendar tracks future PDUFA target dates and scheduled FDA decision deadlines for publicly traded biotech and pharmaceutical companies. Use this calendar to identify potential catalysts before they happen — including upcoming NDA and BLA review deadlines, advisory committee meetings, and expected regulatory milestones.

Each entry includes the target action date and current stock price so you can research potential trades ahead of major FDA decisions.

MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
0 Results
Main Company Current Price Target Date Drug Status Event
Savara Inc. stock logo
SVRA
Savara
$4.22
-7.0%
November 22, 2026 Molgramostim (IMPALA-2) Autoimmune Pulmonary Alveolar Proteinosis (aPAP) 4/15/2026 - PDUFA Date Savara Inc. announced Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Mo…
Full Summary
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$5.93
-3.3%
November 22, 2026 Deramiocel For the Treatment of Duchenne Muscular Dystrophy BLA 8/24/2026 - PDUFA Date Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has extended the Pr…
Full Summary
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.56
+0.6%
November 27, 2026 BBP-418 Limb Girdle Muscular Dystrophy Type 2i (LGMD2i) 5/27/2026 - PDUFA Date BridgeBio Announces that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target actio…
Full Summary
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$31.21
-0.3%
November 30, 2026 bezuclastinib In patients with non-advanced systemic mastocytosis
NDA
5/28/2026 - PDUFA Date Cogent Biosciences, Inc announced The FDA has granted the application Priority Review and assigned …
Full Summary
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$31.21
-0.3%
December 30, 2026 bezuclastinib In patients with non-advanced systemic mastocytosis
NDA
3/16/2026 - PDUFA Date Cogent Biosciences, Inc announced that the Prescription Drug User Fee Act (PDUFA) target action date…
Full Summary
Annexon, Inc. stock logo
ANNX
Annexon
$3.75
-1.6%
H2 2026 ANX007 Geographic Atrophy 9/9/2024 - Data Annexon, Inc. announced that ARCHER II Phase 3 Pivotal Program in GA Underway with Data Expected Se…
Full Summary
Annexon, Inc. stock logo
ANNX
Annexon
$3.75
-1.6%
H2 2026 ANX007 Geographic Atrophy
Phase 3
12/5/2024 - Provided Update Annexon, Inc. Pivotal Phase 3 ARCHER II in GA Actively Enrolling with Data Expected Second Half 2026
Full Summary
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$76.73
-5.0%
H2 2026 KPL-387 In recurrent pericarditis
Phase 2
6/5/2025 - Data Kiniksa Pharmaceuticals International announced that Phase 2 data expected in 2H 2026
Full Summary
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$8.20
+0.5%
H2 2026 Delpacibart Braxlosiran In People Living with Facioscapulohumeral Muscular Dystrophy BLA 6/9/2025 - BLA Filing Avidity Biosciences, Inc. announced that Planning accelerated approval BLA submission in H2 2026
Full Summary
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$6.68
-6.8%
Q4 2026 surabgene lomparvovec for Wet AMD 10/6/2025 - Top-line data REGENXBIO Inc. announced that Topline pivotal data expected in Q4 2026
Full Summary
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$3.99
-6.8%
H2 2026 ADI-001 B cell non-Hodgkin's lymphoma (NHL)
Phase 1
10/16/2025 - Preclinical Data Adicet Bio, Inc. announced that Preliminary clinical data from the Phase 1 trial expected in 2H/2026
Full Summary
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$3.53
-7.8%
Q4 2026 YCANTH™ (cantharidin) For molluscum contagiosum, which is primarily a pediatric disease. 10/20/2025 - Provided Update Verrica is initiating activities to support this regulatory submission, which could be filed as earl…
Full Summary
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$80.39
-3.3%
Q4 2026 Maralixibat Alagille Syndrome 3/16/2026 - Top-line data Mirum Pharmaceuticals, Inc. announced that the Topline data expected in Q4 2026
Full Summary
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$3.75
-2.1%
Q4 2026 ATI-045 In Atopic Dermatitis (AD) 3/18/2026 - Top-line results Aclaris Therapeutics, Inc. announced that the Top line results are expected in the fourth quarter o…
Full Summary
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$11.64
+0.2%
Q4 2026 EDP-978 Treatment of Urticaria 4/13/2026 - Top-line data Enanta Pharmaceuticals, Inc announced that the Topline Data Expected in Q4 2026
Full Summary
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.56
+0.6%
H2 2026 BBO-11818 Potent panKRAS Inhibitor 4/20/2026 - Clinical Data BridgeBio Oncology Therapeutics, Inc. announced that the Updated Phase 1 clinical data are expected …
Full Summary
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$1.45
-9.7%
Q4 2026 ZYNLONTA In patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). 6/30/2026 - Data ADC Therapeutics SA announced that the Full data expected in fourth quarter of 2026
Full Summary
Pfizer Inc. stock logo
PFE
Pfizer
$30.04
-1.3%
Q4 2026 TALZENNA Oral inhibitor of poly ADP-ribose polymerase supplemental New Drug Application (sNDA) Priority Review 7/22/2026 - PDUFA Date Pfizer Inc announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) action date in …
Full Summary
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$19.71
-8.7%
H2 2026 Obicetrapib CETP inhibitor 7/24/2026 - Provided Update NewAmsterdam Pharma Company N.V announced that the European Commission decision expected in 2H26
Full Summary
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$0.40
-5.5%
Q4 2026 DURAVYU In patients with non-proliferative diabetic retinopathy (NPDR). 8/17/2026 - Top-line data EyePoint, Inc. announced that the Topline data from LUCIA, the second pivotal Phase 3 clinical trial…
Full Summary
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$3.99
-6.8%
Q4 2026 ADI-212 treatment of patients with metastatic castration-resistant prostate cancer
Phase 1
8/27/2026 - Initiation Adicet Bio, Inc. announced that The Company plans to initiate Phase 1 enrollment in patients with m…
Full Summary
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$0.95
+4.2%
LATE 2026 CDI-988 For Pandemic Norovirus and Coronavirus 9/9/2026 - Results Cocrystal Pharma, Inc announced that the Preliminary efficacy results expected in late 2026 or ea…
Full Summary
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$3.63
+0.8%
Q4 2026 PRT13722 Oral KAT6A Selective Degrader 9/10/2026 - Enrollment Update Prelude Therapeutics Incorporated announced that the Company expects to begin enrolling patients in…
Full Summary
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$3.30
-2.7%
Q4 2026 CMP-002 treat a broad range of genetic diseases 9/10/2026 - Clinical Trial CAMP4 Therapeutics Corporation announced that the Company anticipates initiation of the clinical tr…
Full Summary
Lipocine Inc. stock logo
LPCN
Lipocine
$1.44
-1.4%
Q4 2026 LPCN 1154 Postpartum depression (PPD) 9/14/2026 - Dose Update Lipocine Inc announced that the first participant dosing expected in early Q4 2026
Full Summary
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.39
+0.3%
Q4 2026 TN-401 For the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by Plakophilin-2 (PKP2) gene mutations. 9/14/2026 - Additional data Tenaya Therapeutics, Inc. announced Additional Data and Updates on Regulatory Discussions Anticipat…
Full Summary
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$6.50
-1.7%
Q4 2026 AXPAXLI In Diabetic Retinopathy 9/15/2026 - NDA submission Ocular Therapeutix, Inc announced that it remains on track to submit the NDA in the fourth quarter …
Full Summary
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$80.15
-1.2%
December 1, 2026 ORKA-001 Inhibitor IL-23p19 9/23/2026 - Data Oruka Therapeutics, announced that the 52-week EVERLAST-A data for all patients expected in Decembe…
Full Summary
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$80.15
-1.2%
Q4 2026 ORKA-001 Inhibitor IL-23p19 9/23/2026 - Data Oruka Therapeutics, announced that the 16-week EVERLAST-B data expected in 4Q 2026
Full Summary
LIFE
Ethos Technologies Inc. Class A Common Stock
$43.10
-1.0%
Q4 2026 Efzofitimod Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) 9/24/2026 - Provided Update aTyr Pharma, Inc. announced that the Company expects to initiate study-related activities in the fo…
Full Summary
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$3.63
+0.8%
Q4 2026 PRT13722 Oral KAT6A Selective Degrader 10/13/2026 - Enrollment Update Prelude Therapeutics Incorporated announced that its on track to initiate enrollment in the fourth…
Full Summary
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$4.41
-6.8%
LATE 2026 ELEVATE-44-201 For Duchenne Muscular Dystrophy 10/14/2026 - Data Entrada Therapeutics, Inc. announced that the Company to receive ELEVATE-44-201 data from Cohort 1 …
Full Summary
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.00
-3.1%
Q4 2026 Anaphylm For epinephrine prodrug candidate product 10/15/2026 - Provided Update Aquestive Therapeutics, Inc. announced that the Ex-U.S. strategy remains on track with Canadian N…
Full Summary
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.47
-0.5%
Q4 2026 Ivonescimab For Lung cancer 10/21/2026 - Clinical Trial Summit Therapeutics Inc. announced Clinical Trial Site Activations in the United States Expected …
Full Summary
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$4.57
-2.9%
January 4, 2027 IBTROZI In Advanced ROS1-Positive Non-Small Cell Lung Cancer supplemental New Drug Application (sNDA) 5/6/2026 - PDUFA Date Nuvation Bio Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted a sup…
Full Summary
Insmed, Inc. stock logo
INSM
Insmed
$93.39
-1.8%
January 28, 2027 ARIKAYCE® IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC supplemental New Drug Application (sNDA) 9/21/2026 - PDUFA Date Insmed Incorporated announced that the FDA granted Priority Review to the sNDA and set a target act…
Full Summary
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.20
+5.0%
January 30, 2027 Leniolisib Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) supplemental New Drug Application (sNDA) 9/25/2026 - PDUFA Date Pharming announced that The application has been granted Priority Review and assigned a Prescriptio…
Full Summary
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$147.33
-2.0%
February 12, 2027 Tinlarebant In Stargardt Disease 8/11/2026 - PDUFA Date Belite Bio, Inc announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) date of Feb…
Full Summary
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$14.37
-3.7%
February 27, 2027 zipalertinib For patients with heavily pre-treated EGFR ex20ins mutation NSCLC
NDA
4/28/2026 - PDUFA Date Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, announced that The…
Full Summary
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$55.95
-1.2%
February 28, 2027 vosoritide Children with achondroplasia supplemental New Drug Application (sNDA) 7/13/2026 - PDUFA Date BioMarin Pharmaceutical Inc. announced that The FDA has set a Prescription Drug User Fee Act (PDUFA…
Full Summary
INmune Bio, Inc. stock logo
INMB
INmune Bio
$1.46
-5.2%
February 1, 2027 Ebstrocel rare and severe genetic skin 10/21/2026 - Marketing authorization INmune Bio Inc. announced that the Full MAA submission targeted for early February 2027
Full Summary
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$11.21
+0.4%
March 10, 2027 onvo-z hereditary angioedema BLA 9/8/2026 - PDUFA Date Intellia Therapeutics, announced that the PDUFA target action date of March 10, 2027
Full Summary
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.00
-3.1%
March 16, 2027 Anaphylm For epinephrine prodrug candidate product
NDA
10/15/2026 - PDUFA Date Aquestive Therapeutics, Inc. announced that the Prescription Drug User Fee Act (PDUFA) goal action…
Full Summary
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$145.25
-1.4%
March 22, 2027 ENFLONSIA™ In Infants Born During or Entering Their First RSV Season sBLA 8/6/2026 - PDUFA Date Merck announced that The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, dat…
Full Summary
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.27
-2.7%
Q1 2027 rezatapopt in patients with advanced solid tumors
NDA
10/24/2025 - NDA Filing PMV Pharmaceuticals, announced that
Full Summary
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$25.04
-2.6%
Q1 2027 zorevunersen For the treatment of Dravet syndrome with a confirmed mutation, 6/30/2026 - rolling submission Stoke Therapeutics, Inc to initiate a rolling New Drug Application (NDA) submission to the U.S. Food…
Full Summary
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$4.40
-1.6%
Q1 2027 PMN310 PMN310 is a novel monoclonal antibody 7/28/2026 - Top-line results ProMIS Neurosciences Inc. announced that 12-month topline results expected in Q1 2027
Full Summary
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$39.39
-2.0%
Q1 2027 Ecopipam To Treat Pediatric Patients With Tourette Syndrome
NDA
8/19/2026 - PDUFA Date Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd announced that the U.S.…
Full Summary
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$15.62
-1.0%
Q1 2027 DYNE-101 Designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus 9/8/2026 - Top-line data Dyne Therapeutics, Inc. announced that the Topline data from the ACHIEVE REC are on track for Q1 20…
Full Summary
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$20.26
-0.5%
Q1 2027 TAK-279 For the Treatment of Active Psoriatic Arthritis
NDA
9/14/2026 - PDUFA Date Takeda announced that the Prescription Drug User Fee Act (PDUFA) target action date is in the first …
Full Summary
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$1.33
-1.5%
Q1 2027 PALI-2108 For patients affected by UC. 9/22/2026 - Dose Update Palisade Bio, Inc. announced that First patient dosing targeted for Q1 2027
Full Summary
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$14.63
-7.5%
Q1 2027 BH-501284 Novel Pan-KRAS Inhibitor
IND
9/28/2026 - IND Submission BlossomHill Therapeutics, Inc. announced that the IND submission in Q1 2027
Full Summary
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$4.41
-6.8%
Q1 2027 ELEVATE-44-201 For Duchenne Muscular Dystrophy 10/14/2026 - Enrollment Update Entrada Therapeutics, Inc. announced that the Cohort 2 enrollment complete with data expected in Q1…
Full Summary
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$0.51
+2.9%
Q1 2027 vensobafusp alfa IgA Nephropathy 10/15/2026 - Expansion Jasper Therapeutics, announces expansion cohort in patients with FSGS, with first patients anticipat…
Full Summary
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$0.95
-5.0%
Q1 2027 intranasal foralumab Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function 10/16/2026 - Top-line data Tiziana Life Sciences, Ltd. announced that Topline data are anticipated to be announced in Q1 2027.
Full Summary
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
$8.72
+1.0%
Q1 2027 DM199 Chronic Kidney Disease Stage II or III 10/22/2026 - Analysis DiaMedica Therapeutics Inc announced that the Interim Analysis Results Expected in Q1 2027
Full Summary
Pharvaris N.V. stock logo
PHVS
Pharvaris
$31.41
+2.4%
April 23, 2027 Deucrictibant For bradykinin-B2-receptor 7/6/2026 - PDUFA Date Pharvaris announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) target action dat…
Full Summary
Organogenesis stock logo
ORGO
Organogenesis
$0.99
-3.6%
April 27, 2027 ReNu for Knee Osteoarthritis 7/6/2026 - PDUFA Date Organogenesis Holdings Inc. announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) …
Full Summary
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$145.04
-7.1%
May 1, 2027 AXS-12 Narcolepsy 7/15/2026 - PDUFA Date Axsome Therapeutics, Inc. announced that the FDA sets PDUFA target action date of May 1, 2027
Full Summary
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.56
+0.6%
May 8, 2027 Encaleret Autosomal Dominant Hypocalcemia Type 1 (ADH1)
NDA
7/22/2026 - PDUFA Date BridgeBio Pharma, Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) …
Full Summary
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$61.58
-2.3%
May 13, 2027 MeziKd Relapsed or Refractory Multiple Myeloma
NDA
7/13/2026 - PDUFA Date Bristol Myers Squibb announced that The U.S. FDA has assigned a target action date of May 13, 2027
Full Summary
Urogen Pharma stock logo
URGN
Urogen Pharma
$34.49
-1.9%
June 14, 2027 UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NDA
10/19/2026 - PDUFA Date UroGen Pharma Ltd. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) ta…
Full Summary
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$31.21
-0.3%
June 29, 2027 bezuclastinib In patients with non-advanced systemic mastocytosis
NDA
9/15/2026 - PDUFA Date Cogent Biosciences, Inc. announced that the assigned a Prescription Drug User Fee Act (PDUFA) target…
Full Summary
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
$29.36
+0.6%
H1 2027 NANORAY-312 head and neck squamous cell cancers. 10/24/2025 - Interim Data Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the req…
Full Summary
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$87.63
+2.2%
Q2 2027 KSI-101 in patients with MESI 8/6/2026 - Top-line data Kodiak Sciences Inc. announced that the topline clinical data release anticipated in 2Q 2027
Full Summary
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$0.40
-5.5%
H1 2027 DURAVYU In patients with non-proliferative diabetic retinopathy (NPDR). 8/17/2026 - NDA submission EyePoint, Inc. announced that the potential FDA New Drug Application submission planned for 1H 2027
Full Summary
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$18.26
-3.6%
H1 2027 telitacicept Sjögren's Disease 9/8/2026 - Top-line results Vor Bio announced Topline results from the 24-week primary endpoint remain expected in the first ha…
Full Summary
OPTH
Optimi Health
$3.25
-0.9%
H1 2027 psilocybin-assisted therapy for Major Depressive Disorder 9/10/2026 - Trial Initiation Optimi Health Corp announced that the trial is planned to be initiated in the first half of 2027
Full Summary
Organon & Co. stock logo
OGN
Organon & Co.
$13.76
+0.0%
Q2 2027 MIUDELLA Hormone-Free Intrauterine Device 9/14/2026 - PDUFA Date Organon announced that the Prescription Drug User Fee Act (PDUFA) action expected in the second quar…
Full Summary
Envoy Medical, Inc. stock logo
COCH
Envoy Medical
$0.60
-0.1%
Q2 2027 Acclaim for Breakthrough Hearing Device 10/12/2026 - Provided Update Envoy Medical® announced that the Advances Toward Targeted Completion of the Final Clinical Module …
Full Summary
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
$4.07
+1.4%
Q2 2027 QRX003 Nethertons Syndrome 10/20/2026 - Top-line data Quoin Pharmaceuticals Ltd. announced that the Topline Data Expected in Q2 2027
Full Summary
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$14.59
-2.1%
Q2 2027 JADE101 For the treatment of IgA nephropathy (IgAN) 10/21/2026 - Highlights Jade Biosciences, Inc. announced that the JUNIPER Phase 2 Trial-in-Progress poster highlights ongoi…
Full Summary
INmune Bio, Inc. stock logo
INMB
INmune Bio
$1.46
-5.2%
Q2 2027 Ebstrocel rare and severe genetic skin BLA 10/21/2026 - Provided Update INmune Bio Inc. announced that the U.S. BLA expected to be submitted in Q2, 2027
Full Summary
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$10.19
-3.3%
H1 2027 CLYM116 for IgAN 10/23/2026 - Initial Data Climb Bio, Inc. announced that the NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in…
Full Summary
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
$5.46
-1.1%
Q3 2027 GTB-5550 Multiple Myeloma
Phase 1
9/15/2026 - Dose escalation GT Biopharma, Inc announced that the Phase 1 dose escalation basket trial with GTB-5550 in solid t…
Full Summary
LB Pharmaceuticals Inc stock logo
LBRX
LB Pharmaceuticals
$38.73
-1.8%
H2 2027 LB-102 In Patients With Bipolar Depression 3/25/2026 - Top-line data LB Pharmaceuticals Inc announced that the Topline data expected in 2H 2027
Full Summary
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.30
-2.5%
H2 2027 Belzupacap Sarotalocan (AU-011) Non-Muscle Invasive Bladder Cancer (NMIBC) 6/1/2026 - Top-line data Aura Biosciences Announced that the Topline data for the 15-month primary endpoint are anticipated…
Full Summary
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$42.93
-2.2%
H2 2027 ION582 Angelman syndrome 7/6/2026 - Top-line data Ionis Pharmaceuticals, Inc announced Topline data from REVEAL anticipated in 2H 2027 -
Full Summary
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$0.40
-5.5%
Q4 2027 DURAVYU In patients with non-proliferative diabetic retinopathy (NPDR). 7/30/2026 - Top-line data EyePoint, Inc. announced that Topline data for both DME trials are anticipated in the fourth quart…
Full Summary
OPTH
Optimi Health
$3.25
-0.9%
LATE 2027 psilocybin-assisted therapy for Major Depressive Disorder 9/10/2026 - Dose Update Optimi Health Corp. announced that the dosing expected to be complete by the end of 2027.
Full Summary
Alkermes plc stock logo
ALKS
Alkermes
$43.63
-1.2%
LATE 2027 ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Phase 2
9/21/2026 - Data Alkermes plc announced that the Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling, Data Ex…
Full Summary
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$2.77
+0.4%
Q4 2027 EB06 Moderate-To-Severe Nonsegmental Vitiligo 10/15/2026 - Top-line data Edesa anticipates that topline data will be available fourth quarter 2027.
Full Summary
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$9.33
-9.3%
H2 2027 STRO-006 In Patients With Range Of Solid Tumors 10/21/2026 - Initial Data Sutro Biopharma, Inc announced that the Initial clinical data expected in the second half of 2027
Full Summary
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$1.33
-1.5%
Q1 2028 PALI-2108 For patients affected by UC. 9/22/2026 - primary efficacy readout Palisade Bio, Inc. announced that primary efficacy readout (Week 12 endoscopic response) targeted …
Full Summary

Frequently Asked Questions

The PDUFA date (Prescription Drug User Fee Act) is the FDA’s target deadline to approve or reject a New Drug Application (NDA) or Biologics License Application (BLA). These are major catalysts for biotech stocks, as a decision often triggers significant price movement.

A grant refers to an award of a designation (i.e., RMAT), while a target date usually refers to a PDUFA date (the FDA’s deadline to act on an NDA or BLA).

A submission occurs when a company files an NDA, BLA or supplemental application. If the FDA accepts the application, it enters review and may receive a PDUFA target date. Approval means the FDA has authorized the drug or new indication for marketing. An accepted application or scheduled target date does not guarantee approval.

This calendar includes announced PDUFA target dates, expected FDA decision dates, anticipated NDA and BLA filings, advisory committee meetings, clinical trial data readouts and other scheduled regulatory milestones reported by publicly traded biotechnology and pharmaceutical companies.

No. Some events have exact dates announced by the FDA or the company, while others are company estimates expressed as a month, quarter or half-year. Estimated dates may change as clinical trials, submissions and regulatory reviews progress.

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process